Status:
UNKNOWN
Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children
Lead Sponsor:
University of Ghana Medical School
Collaborating Sponsors:
University of Copenhagen
Conditions:
Uncomplicated Malaria
Eligibility:
All Genders
6-14 years
Phase:
PHASE3
Brief Summary
Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recomm...
Eligibility Criteria
Inclusion
- microscopically confirmed acute uncomplicated falciparum malaria;
- temperature at screening 37.50C or more or history of fever 24 preceding enrollment;
- willingness to comply with follow up schedule;
- written informed consent by accompanying parent or guardian
Exclusion
- features of severe malaria or danger signs of malaria
- known intolerance or allergy to any of the study medications
- known treatment with any of the study medications in the month preceding enrollment
- serious underlying disease that may mask outcome assessment
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00406146
Start Date
October 1 2004
End Date
December 1 2006
Last Update
December 4 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korle Bu Teaching Hospital
Accra, Ghana